Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Deborah J. Andrews

At a glance: Deborah J. Andrews is Director at Lineage Cell Therapeutics (LCTX). Their latest SEC Form 4, filed Nov 17, 2026, reported a purchase of $20K. On file: 1 purchase line ($20K) and 0 sale lines ($0).

Disclosed holdings: about $34K of LCTX stock: 40,578 shares reported on their latest Form 4 (filed Nov 17, 2026), valued at the Nov 19, 2026 close of $0.83. This counts only LCTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Lineage Cell Therapeutics, Inc. (LCTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys+$762
Total bought / sold$20K / $0

Reported trades

Filed Stock Type Shares Price Value Since
Nov 17SEC LCTXLineage Cell Therapeutics, Inc.First buyStake +160% Buy 25,00040,578 held (+160%) $0.80 $20K +3.8%
  • Buy

    Director Deborah J Andrews bought $20K of LCTX at $0.80 — first open-market purchase in our records; raises the stake by 160%.

Follow Deborah J. Andrews

Get one email when Deborah J. Andrews files a new purchase or sale. Free.

At most one email a day about Deborah J. Andrews, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.